Amgen Stock Hits New Lows Amid Patent Expirations
Amgen (NASDAQ:AMGN) is one of the leading players in the healthcare sector, and its stock has been a subject of interest among investors. The company's recent performance and future prospects have been analyzed by market experts.
The pharmaceutical giant has seen a significant decline in its shares over the past year, with a 34% drop in price since January 2022. This decrease can be attributed to various factors, including increased competition from generic medications and patent expirations of some of its popular products.
Despite these challenges, Amgen's pipeline is rich in promising treatments for various diseases, including cancer, cardiovascular conditions, and rare genetic disorders. The company's commitment to innovation and research has resulted in several FDA approvals and partnerships with other industry leaders.